Maternal 6-valent group B Streptococcus vaccine in non-pregnant and pregnant females: a randomized phase 1/2 trial.

Summary

This randomized phase 1/2 trial evaluated an investigational maternal hexavalent group B Streptococcus polysaccharide-protein conjugate vaccine in non-pregnant and pregnant participants and their infants. The study directly addresses prevention of neonatal invasive GBS disease, a major cause of infant morbidity and mortality for which no licensed vaccine currently exists.

Key Findings

• A randomized phase 1/2 trial evaluated the investigational hexavalent GBS6 vaccine in non-pregnant and pregnant females and their infants.
• The study targeted prevention of neonatal GBS disease, a major cause of infant morbidity and mortality.
• The trial represents clinical development of a maternal vaccine despite the absence of any licensed capsular polysaccharide conjugate GBS vaccine.

Clinical Implications

The findings support continued clinical development of maternal GBS vaccination and inform future efficacy trials designed to measure prevention of neonatal invasive disease. Implementation would require assessment of gestational timing, infant antibody persistence, vaccine safety, cost-effectiveness, and regional GBS epidemiology.

Limitations

• The supplied abstract does not provide the complete efficacy, immunogenicity, or safety results.
• Phase 1/2 data cannot establish population-level prevention of neonatal invasive GBS disease.
• Long-term infant protection and effectiveness across different geographic serotype distributions require further study.

Future Directions

Large phase 3 efficacy trials should assess prevention of neonatal invasive GBS disease, stillbirth, and infant mortality, while evaluating maternal and infant safety, antibody correlates of protection, durability, and cost-effectiveness in diverse settings.